{
    "xml": "<topic id=\"PHP81626\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/budenofalk-capsules\" basename=\"budenofalk-capsules\" title=\"Budenofalk capsules\">\n<title>Budenofalk<tm tmtype=\"reg\"/> capsules</title>\n<topic id=\"PHP83713\" outputclass=\"indicationsAndDose\" rev=\"1.30\" parent=\"/clinical-medicinal-product-information/budenofalk-capsules\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Mild to moderate Crohn's disease affecting the ileum or ascending colon</p>\n<p outputclass=\"therapeuticIndication\">Chronic diarrhoea due to collagenous colitis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>3&#8239;mg 3 times a day for up to 8 weeks, reduce dose for the last 2 weeks of treatment.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Autoimmune hepatitis, induction of remission</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>3&#8239;mg 3 times a day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Autoimmune hepatitis, maintenance</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>3&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP83737\" outputclass=\"nationalFunding\" rev=\"1.14\" parent=\"/clinical-medicinal-product-information/budenofalk-capsules\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (April 2015) that <i>Budenofalk</i>\n<tm tmtype=\"reg\"/> gastro-resistant capsules are accepted for restricted use within NHS Scotland for the treatment of autoimmune hepatitis in non-cirrhotic patients who are intolerant of conventional oral corticosteroids (prednisolone) with severe corticosteroid-related side effects (actual or anticipated) such as psychosis, poorly controlled diabetes or osteoporosis.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP81626",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/budenofalk-capsules",
    "basename": "budenofalk-capsules",
    "title": "Budenofalk capsules",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Mild to moderate Crohn's disease affecting the ileum or ascending colon",
                        "html": "Mild to moderate Crohn's disease affecting the ileum or ascending colon"
                    },
                    {
                        "textContent": "Chronic diarrhoea due to collagenous colitis",
                        "html": "Chronic diarrhoea due to collagenous colitis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "3 mg 3 times a day for up to 8 weeks, reduce dose for the last 2 weeks of treatment.",
                        "html": "<p>3&#8239;mg 3 times a day for up to 8 weeks, reduce dose for the last 2 weeks of treatment.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Autoimmune hepatitis, induction of remission",
                        "html": "Autoimmune hepatitis, induction of remission"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "3 mg 3 times a day.",
                        "html": "<p>3&#8239;mg 3 times a day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Autoimmune hepatitis, maintenance",
                        "html": "Autoimmune hepatitis, maintenance"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "3 mg twice daily.",
                        "html": "<p>3&#8239;mg twice daily.</p>"
                    }
                ]
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (April 2015) that Budenofalk gastro-resistant capsules are accepted for restricted use within NHS Scotland for the treatment of autoimmune hepatitis in non-cirrhotic patients who are intolerant of conventional oral corticosteroids (prednisolone) with severe corticosteroid-related side effects (actual or anticipated) such as psychosis, poorly controlled diabetes or osteoporosis.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (April 2015) that <i>Budenofalk</i> <tm tmtype=\"reg\"/> gastro-resistant capsules are accepted for restricted use within NHS Scotland for the treatment of autoimmune hepatitis in non-cirrhotic patients who are intolerant of conventional oral corticosteroids (prednisolone) with severe corticosteroid-related side effects (actual or anticipated) such as psychosis, poorly controlled diabetes or osteoporosis.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}